Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124570724> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W3124570724 endingPage "181" @default.
- W3124570724 startingPage "172" @default.
- W3124570724 abstract "Background: In the human population, CYP2D6 is highly polymorphic group of genes involved in metabolizing ~25% of all clinically used neuroleptic and antidepressant drugs. The CYP2D6*4 and CYP2D6*10 variants are prevalent in Asian population exhibiting variable drug metabolizing ability thereby affecting drug therapeutic responses. Objective: To determine the genotypic frequencies of CYP2D6*1 (Normal metabolizer), *4 (Poor metabolizer) and *10 (Intermediate metabolizer) variants among schizophrenic subjects and control group from a sub-set of Karachi population. Methods: Genomic Deoxyribonucleic Acid (gDNA) was extracted and amplified with CYP2D6*4 and *10 primers using Polymerase Chain Reaction (PCR) and digested by Bacillus stereothermophilus (BstN1) and Hemophilus parahemolyticus (Hph1) restriction enzymes. The digested gDNA bands were identified as wild type or mutants and their genotypic frequencies were estimated by Hardy-Weinberg Equation (HWE). Results: In normal subjects, frequencies of CYP2D6*1 wild allele (57%) coded functional enzyme, CYP2D6*4 variant (9%) producing non-functional enzyme and CYP2D6*10 allele (70%) producing altered enzyme with reduced activity that was most prevalent in schizophrenic patients. Discussion: Drug response is a complex phenomenon that is governed by genetic and environmental factors. Antipsychotic drug metabolism among schizophrenic patients with variable drug responsesis related to CYP2D6 polymorphism. Clinically, it is imperative to differentiate between responders and non-responders using the treatment, otherwise the drug will be either nonefficacious or toxic to the patients. Therefore, a gene testing system needs to be established to identify patient’s genotype(s) predicting whether they are normal, poor, intermediate or ultrarapid drug metabolizer thereby allowing clinicians to adjust dose(s) of antipsychotic drug(s). Conclusion : Genotyping of CYP2D6 alleles among schizophrenic patients indicated prevalence of *4 and *10 variants in Karachi population producing non-functional (poor metabolizer) and reduced functional (intermediate metabolizer) drug metabolizing enzymes phenotypes, respectively. Hence, dose adjustment is crucial otherwise schizophrenia condition will not be improved satisfactorily. Therefore, CYP2D6 gene screening program should be included in clinical practice to help clinicians to prescribe appropriate doses according to patient’s genotype and minimize sufferings of schizophrenics including side effects of drug that might occur at high drug concentrations." @default.
- W3124570724 created "2021-02-01" @default.
- W3124570724 creator A5003194819 @default.
- W3124570724 creator A5018994924 @default.
- W3124570724 creator A5067066989 @default.
- W3124570724 date "2021-02-01" @default.
- W3124570724 modified "2023-10-18" @default.
- W3124570724 title "Gene Frequency of CYP2D6*4 and *10 Variants in Karachi Population" @default.
- W3124570724 doi "https://doi.org/10.2174/1875692117999201014162804" @default.
- W3124570724 hasPublicationYear "2021" @default.
- W3124570724 type Work @default.
- W3124570724 sameAs 3124570724 @default.
- W3124570724 citedByCount "0" @default.
- W3124570724 crossrefType "journal-article" @default.
- W3124570724 hasAuthorship W3124570724A5003194819 @default.
- W3124570724 hasAuthorship W3124570724A5018994924 @default.
- W3124570724 hasAuthorship W3124570724A5067066989 @default.
- W3124570724 hasConcept C104317684 @default.
- W3124570724 hasConcept C135763542 @default.
- W3124570724 hasConcept C175239580 @default.
- W3124570724 hasConcept C2908647359 @default.
- W3124570724 hasConcept C33664856 @default.
- W3124570724 hasConcept C37463918 @default.
- W3124570724 hasConcept C54355233 @default.
- W3124570724 hasConcept C55775858 @default.
- W3124570724 hasConcept C71924100 @default.
- W3124570724 hasConcept C86803240 @default.
- W3124570724 hasConcept C98274493 @default.
- W3124570724 hasConcept C99454951 @default.
- W3124570724 hasConceptScore W3124570724C104317684 @default.
- W3124570724 hasConceptScore W3124570724C135763542 @default.
- W3124570724 hasConceptScore W3124570724C175239580 @default.
- W3124570724 hasConceptScore W3124570724C2908647359 @default.
- W3124570724 hasConceptScore W3124570724C33664856 @default.
- W3124570724 hasConceptScore W3124570724C37463918 @default.
- W3124570724 hasConceptScore W3124570724C54355233 @default.
- W3124570724 hasConceptScore W3124570724C55775858 @default.
- W3124570724 hasConceptScore W3124570724C71924100 @default.
- W3124570724 hasConceptScore W3124570724C86803240 @default.
- W3124570724 hasConceptScore W3124570724C98274493 @default.
- W3124570724 hasConceptScore W3124570724C99454951 @default.
- W3124570724 hasIssue "3" @default.
- W3124570724 hasLocation W31245707241 @default.
- W3124570724 hasOpenAccess W3124570724 @default.
- W3124570724 hasPrimaryLocation W31245707241 @default.
- W3124570724 hasRelatedWork W13097937 @default.
- W3124570724 hasRelatedWork W13587973 @default.
- W3124570724 hasRelatedWork W14463554 @default.
- W3124570724 hasRelatedWork W2947138 @default.
- W3124570724 hasRelatedWork W3207556 @default.
- W3124570724 hasRelatedWork W3998160 @default.
- W3124570724 hasRelatedWork W4564883 @default.
- W3124570724 hasRelatedWork W8771793 @default.
- W3124570724 hasRelatedWork W9167010 @default.
- W3124570724 hasRelatedWork W9210744 @default.
- W3124570724 hasVolume "17" @default.
- W3124570724 isParatext "false" @default.
- W3124570724 isRetracted "false" @default.
- W3124570724 magId "3124570724" @default.
- W3124570724 workType "article" @default.